Module 3 includes NTRK2, DDR2, and STAT5B, which have been associated with prostate tumor metastasis (96–98), and JAZF1, ZEB1, and BCL2, which have been linked to cancer progression and resistance to chemotherapy (99–101). Here, BCL2 is linked to prostate neoplasm.